MedCity News

March 23, 2016

By Chris Seper

MedCity INVEST – April 12-13 in Chicago

At MedCity INVEST, active investors connect with corporate business development executives to facilitate investment opportunities with over 40 of the most promising healthcare start-ups that span the biotech, medical device, digital health, diagnostics, pharma, and regenerative medicine sectors.

Over 300 healthcare experts, industry leaders, active investors and entrepreneurs will be in attendance at this premier healthcare investing event April 12-13 in Chicago to discuss the latest trends in investing, the business of medicine, the best opportunities and more.

INVEST will feature three leading healthcare leaders who will describe new approaches to healthcare, what’s working, what’s not and their vision of the future. They are:

Bruce Bloom, President and Chief Science Officer, Cures Within Reach (@CuresWReach)

Beg, Borrow and Steal: Repurposing Non-Healthcare Financial Instruments to Drive New Treatments to Patients
Bloom will describe how financial instruments used in other business sectors can be repurposed in healthcare: to deliver more treatments, reduce and manage direct healthcare costs, positively impact patients and payers, and provide opportunity for investors and industry.

Dr. Bruce Bloom is President and CSO of Cures Within Reach, a charity saving lives by repurposing approved drugs and devices to deliver a dozen fast, safe and affordable treatments for diseases that had no effective therapy. He founded CureAccelerator™, the global online repurposing research collaboration platform driving more treatments to more patients more quickly.

Register today and save.

Read Full Article Here.

Global Genes RARECast with Daniel Levine

January 27, 2016

The high cost and long time it takes to develop drugs has people looking for alternative strategies for finding new treatments. One such approach is repurposing—finding new uses for already approved drugs. This is particularly compelling for rare diseases where small patient populations can serve as a disincentive to drug developers and the need for therapeutics is largely unmet. We spoke to Bruce Bloom, president and chief science officer of Cures Within Reach, which launched the crowdsourcing platform CureAccelerator to fund repurposing research for rare diseases. Bloom discussed the benefits of repurposing, how the CureAccelerator will work, and why he believes the initiative could help to build a new approach to repurposing research and developing treatments for rare disease. Listen to the full episode here!

Assay and Drug Development Technologies, Volume 13 Issue 10

December 21, 2015

Bruce E. Bloom

Repurposing research improves patient lives by taking drugs approved for one disease and clinically testing them to create a treatment for a different disease. Repurposing drugs that are generic, inexpensive, and widely available and that can be taken in their current dosage and formulation in the new indication provide a quick, affordable, and effective way to create

Clinical Informatics News, December 3, 2015

Allison Proffitt

For severely ill children with a rare disease called autoimmune lymphoproliferative syndrome (ALPS), dead white blood cells build up in the organs instead of being broken down normally. But two pills a day of a drug approved for use after kidney transplants gives some total remission of their disease.

A laser developed to treat epilepsy can be trained on a cancerous prostate, killing the cancerous cells but not damaging the surrounding nerves, the bowel, or other critical structures.

PharmaTimes Magazine, November/December 2015

George Underwood

The use of approved, well-known medicines to treat patients with entirely different conditions is a tried-and-tested formula for pharma companies, even when the discoveries are largely serendipitous. Using prostate-shrinking finasteride in hair regrowth, beta-blocker propranolol in infants with abnormal blood vessels and cancer-beating bevacizumab in age-related macular degeneration were all strokes of luck that proved highly effective.


November 19, 2015

Findacure has teamed up with the US-based Cures Within Reach to help develop the concept of social investment for rediscovery research for fundamental diseases. Dr Bruce Bloom of Cures Within Reach explains how this works:

Rediscovery research improves lives by taking drugs approved for one disease and repurposing them to create a new treatment in a different disease. When the repurposed drug is generic and able to be taken in the current dosage and formulation, there is often little or no profit to be gained, so industry does not fund these repurposing projects. Currently, philanthropy funds them, and that funding is hard to get.

Science Translational Medicine, via PRNewswire

November 12, 2015

Researchers have taken a significant step forward in developing gene therapy against a fatal neurodegenerative disease that strikes children. By delivering a working version of a gene to produce a key enzyme that is lacking in Batten disease, the scientists delayed symptoms and extended lifespan in dogs with a comparable disease.

Nature Reviews Clinical Oncology, October 20, 2015

Francesco Bertolini, Vikas P. Sukhatme & Gauthier Bouche

In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols. The potential benefits are so relevant that funding of academically and/or independently driven preclinical and clinical research programmes should be considered at both national and international levels.

Pharmaceutical Technology, Volume 39 Issue 17

August 6, 2015

A. Shanley

Outsourcing opportunity?

PharmTech: What role do contract research organizations (CROs) and contract manufacturing organizations (CMOs) play in drug repurposing? Are there any new business models that you are seeing in CMOs that work in this area?

The Pharmaceutical Journal, June 18, 2015

Malini Guha 

In his laboratory at the Beth Israel Deaconess Medical Center in Boston, Massachusetts, Harvard professor Vikas Sukhatme has identified several surface markers found on a type of immune cell called a myeloid-derived suppressor cell (MDSC).

March 2015

Northwestern Mutual Wealth Management Advisor Steve Braun recently received a 2015 Community Service Award as the Most Exceptional Volunteer for his work with Cures Within Reach.  Learn about our Executive Board member, Steve Braun, and his efforts to support our growth.  Steve Braun's Community Involvement



Part II: Business Review

Drug Discovery World, Spring 2015

Dr. Stephen Naylor, David M. Kauppi and Judge M. Schonfeld

There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.The activity and productivity of DRPx focused companies as well as pharmaceutical company efforts appear to offer some encouragement in providing solutions to the myriad of problems the industry faces at the present time.These efforts can only be sustained and expanded if the dynamic variables of viable and creative business models are identified and understood. In this work we describe the lessons that can be learnt from surveying the landscape of the DRPx industry.This analysis includes both the successes and the failures of past DRPx companies.We introduce the various stakeholders that are shifting the decision process of DRPx implementation and acceptance away from the pharmaceutical industry. In addition the component pieces necessary to enhance the value of a DRPx company are discussed and the top 10 mini- blockbuster and blockbuster DRPx drugs are introduced. Finally, we assess and compare an assortment of DRPx business models and evaluate the current climate of the DRPx industry.

Read Full Article Here

MILWAUKEE, March 11, 2015 PRNewswire

Whether it's becoming a Big Brother, setting up a lemonade stand or advocating for economic and social equality for women and girls, Northwestern Mutual financial representatives are actively involved in their communities. To recognize this, Northwestern Mutual, through its foundation, is awarding financial representatives with the company's 2015 Community Service Award.

Three winners in each of the four regions will receive a $15,000 or $20,000 grant for their nonprofit, while an additional winner per region is named most exceptional, earning $25,000 for their organization. In total, the foundation is awarding $285,000 in grants.

"Each year I'm overwhelmed by the outstanding work our financial representatives are doing in their communities and their strong spirit of giving is echoed across our company each day," said John Kordsmeier, president, Northwestern Mutual Foundation. "The impact of these individuals extends our business and reaches the heart of what we do every day by putting others first."

Sign up for our eNewsletter today!


First Name


Cures Within Reach

Illinois Science+Technology Park

8025 Lamon Avenue, Suite 440

Skokie, IL 60077



Sunday the 30th. copyright 2015 Cures Within Reach.